Achieve Life Sciences $ACHV

Health Care

Achieve Life Sciences is no longer publicly traded under ACHV. The ticker stopped returning market quotes on Nov 22, 2026, which usually means the company was delisted, acquired or taken private.

Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Aug 13, 2026, the first target we tracked for ACHV.

Achieve Life Sciences (ACHV) is a Health Care company in the Russell 2000.

Analyst price targets on ACHV

Current price targets from 4 firms average $14.5, median $13, ranging from $12 to $20. Each is tracked to its date and scored the same way a member's call is.

4 targets, newest first. Open a row for its source and scoring.

DateAug 13, 2026 FirmRaymond James RatingStrong Buy · initiates Targetat $7.25 · $20 +176% Horizonby Aug 2027 StatusOpen

Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +176% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 13, 2027.

Source Morgan Stanley initiates Achieve Life Sciences stock at overweight Investing.com · Aug 13, 2026 · opens the publisher's site
Raymond James resumed coverage with a Strong Buy rating and set a $20.00 price target
DateAug 13, 2026 FirmCanaccord Genuity RatingBuy · reiterates Targetat $7.25 · $13 +79% Horizonby Aug 2027 StatusOpen

Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +79% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 13, 2027.

Source Morgan Stanley initiates Achieve Life Sciences stock at overweight Investing.com · Aug 13, 2026 · opens the publisher's site
Canaccord Genuity also reiterated a Buy rating with a $13.00 price target
DateAug 13, 2026 FirmH.C. Wainwright RatingBuy · reiterates Targetat $7.25 · $12 +66% Horizonby Aug 2027 StatusOpen

Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +66% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 13, 2027.

Source Morgan Stanley initiates Achieve Life Sciences stock at overweight Investing.com · Aug 13, 2026 · opens the publisher's site
H.C. Wainwright reiterated its Buy rating on the company, maintaining a $12.00 price target
DateAug 13, 2026 FirmMorgan Stanley RatingOverweight · initiates Targetat $7.25 · $13 +79% Horizonby Aug 2027 StatusOpen

Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +79% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.

Scoring Open: judged on the close on Aug 13, 2027.

Source Morgan Stanley initiates Achieve Life Sciences stock at overweight Investing.com · Aug 13, 2026 · opens the publisher's site
Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a price target of $13.00.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Achieve Life Sciences revenue & net income history (FY2016–FY2025)

RevenueNet income
$0−$27.3M−$54.6MFY2016 net income: −$1.23M'16FY2017 net income: −$10.6M'17FY2018 revenue: $0FY2018 net income: −$12.7M'18FY2019 revenue: $0FY2019 net income: −$16.4M'19FY2020 net income: −$14.7M'20FY2021 net income: −$33.2M'21FY2022 net income: −$42.4M'22FY2023 net income: −$29.8M'23FY2024 net income: −$39.8M'24FY2025 net income: −$54.6M'25
Achieve Life Sciences annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue——$0$0——————
Net income−$1.23M−$10.6M−$12.7M−$16.4M−$14.7M−$33.2M−$42.4M−$29.8M−$39.8M−$54.6M
EPS (diluted)−$232500.00−$8828.00−$72.29−$39.76−$5.42−$4.08−$4.00−$1.50−$1.24−$1.25
Balance sheet
Cash and equivalents$15.0K$5.28M$9.52M$16.7M$35.9M$43.0M$24.8M$15.5M$12.8M$20.9M
Total assets$3.81M$9.89M$19.1M$21.1M$40.3M$47.5M$30.0M$19.4M$38.6M$41.8M
Total liabilities$3.20M$2.01M$3.28M$3.03M$3.01M$19.5M$21.7M$20.8M$17.7M$20.3M
Shareholders' equity$610.0K—$15.8M$18.1M$37.3M$28.0M$8.30M−$1.45M$20.9M$21.5M
Cash flow
Operating cash flow−$202.0K−$9.11M−$10.6M−$15.2M−$13.5M−$29.4M−$37.6M−$24.5M−$29.8M−$49.5M
Capital expenditure$46.0K—$46.0K$53.0K$17.0K——$21.0K—$3.00K
Free cash flow−$248.0K—−$10.7M−$15.3M−$13.5M——−$24.5M—−$49.5M

From Achieve Life Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Achieve Life Sciences in the news

Nov 9, 2026 Investing.com Achieve Life Sciences rebrands as AchieveRx, changes ticker to QUIT
Aug 13, 2026 Investing.com Morgan Stanley initiates Achieve Life Sciences stock at overweight Target

About Achieve Life Sciences

Headquarters
Seattle, Washington From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →